CLINICAL_TRIALS
trial_result
· 2021-05-11
Clinical Trial Update: Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy [Phase 2]
Summary
Phase 2 trial evaluating aprepitant as antiemetic prophylaxis in patients with acute myeloid leukemia undergoing induction chemotherapy has completed with poste…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University Health Network, Toronto | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2021-05-11